

RealRate

CONSULTING & SERVICES 2023



Pharma Bio Serv Inc Rank 2 of 33







CONSULTING & SERVICES 2023





Pharma Bio Serv Inc Rank 2 of 33

The relative strengths and weaknesses of Pharma Bio Serv Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharma Bio Serv Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 186% points. The greatest weakness of Pharma Bio Serv Inc is the variable Revenue from Contract with Customer, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 226%, being 285% points above the market average of -59%.

Input Variable	Value in 1000 USD
Assets, Current	19,944
Assets, Noncurrent	205
Cost of Revenues	14,517
General And Administrative Expense	3,707
Intangible Assets	0
Labor Expense	0
Liabilities, Current	2,108
Liabilities, Non-Current	347
Operating Lease Assets	503
Other Assets	0
Other Compr. Net Income	94
Other Expenses	182
Other Liabilities	1,639
Other Net Income	13

Output Variable	Value in 1000 USD
Assets	20,651
Liabilities	4,093
Expenses	18,405
Revenues	19,399
Stockholders Equity	16,558
Net Income	1,007
Comprehensive Net Income	1,100
Economic Capital Ratio	226%





RealRate

CONSULTING & SERVICES 2023



Pharma Bio Serv Inc Rank 2 of 33

Input Variable	Value in 1000 USD
Other Revenues	19,399
Revenue from Contract with Customer	0
Revenue from Reimbursement	0

